(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199347 A1

(51) International Patent Classification:
A61K 31/57 (2006.01) *A61P 21/00* (2006.01)
A61K 31/56 (2006.01) *C07J 7/00* (2006.01)
A61K 31/573 (2006.01)

(21) International Application Number:
PCT/US2025/020739

(22) International Filing Date:
20 March 2025 (20.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/567,996 21 March 2024 (21.03.2024) US

(71) Applicant: **REVERAGEN BIOPHARMA, INC.** [US/US]; 155 Gibbs Street, Suite 433, Rockville, Maryland 20850 (US).


(72) Inventors: **HOFFMAN, Eric**; c/o ReveraGen BioPharma, Inc., 155 Gibbs Street, Suite 433, Rockville, Maryland 20850 (US). **HAGERTY, Laura**; c/o ReveraGen BioPharma, Inc., 155 Gibbs Street, Suite 433, Rockville, Maryland 20850 (US). **DAMSKER, Jesse**; c/o ReveraGen BioPharma, Inc., 155 Gibbs Street, Suite 433, Rockville, Maryland 20850 (US).

(74) Agent: **LARSEN, Erik, M.** et al.; P.O. Box 70250, Oakland, California 94612-0250 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: TREATMENT OF GLOMERULONEPHRITIS



Experimental timeline. Female WT (MRL) and lupus (MRL-lpr) mice arrived at 8 weeks of age. At 12 weeks, blood (submental) was collected and daily treatment with vamorolone (vam; 30 mg/kg), prednisolone (pred; 10 mg/kg) or vehicle began. Mice were euthanized after 8 weeks of treatment.

FIG. 9

(57) Abstract: The present disclosure provides methods of treating or reducing the symptoms of glomerulonephritis in a subject.

WO 2025/199347 A1

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*